Literature DB >> 19208384

The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome.

Christina Zaleski1, Anne S Bassett, Karen Tam, Andrea L Shugar, Eva W C Chow, Elizabeth McPherson.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19208384      PMCID: PMC3295831          DOI: 10.1002/ajmg.a.32650

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


× No keyword cloud information.
  20 in total

1.  The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.

Authors:  M Białecka; M Droździk; G Kłodowska-Duda; K Honczarenko; B Gawrońska-Szklarz; G Opala; J Stankiewicz
Journal:  Acta Neurol Scand       Date:  2004-10       Impact factor: 3.209

2.  Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat.

Authors:  C J Pycock; C J Carter; R W Kerwin
Journal:  J Neurochem       Date:  1980-01       Impact factor: 5.372

3.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.

Authors:  J S Rakshi; T Uema; K Ito; D L Bailey; P K Morrish; J Ashburner; A Dagher; I H Jenkins; K J Friston; D J Brooks
Journal:  Brain       Date:  1999-09       Impact factor: 13.501

4.  A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population.

Authors:  Lorenzo D Botto; Kristin May; Paul M Fernhoff; Adolfo Correa; Karlene Coleman; Sonja A Rasmussen; Robert K Merritt; Leslie A O'Leary; Lee-Yang Wong; E Marsha Elixson; William T Mahle; Robert M Campbell
Journal:  Pediatrics       Date:  2003-07       Impact factor: 7.124

Review 5.  Neuropsychological and perceptual defects in Parkinson's disease.

Authors:  Ivan Bodis-Wollner
Journal:  Parkinsonism Relat Disord       Date:  2003-08       Impact factor: 4.891

6.  Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden.

Authors:  S Oskarsdóttir; M Vujic; A Fasth
Journal:  Arch Dis Child       Date:  2004-02       Impact factor: 3.791

7.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

Authors:  Stephen K Van Den Eeden; Caroline M Tanner; Allan L Bernstein; Robin D Fross; Amethyst Leimpeter; Daniel A Bloch; Lorene M Nelson
Journal:  Am J Epidemiol       Date:  2003-06-01       Impact factor: 4.897

8.  Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22.

Authors:  L E Krahn; D M Maraganore; V V Michels
Journal:  Mayo Clin Proc       Date:  1998-10       Impact factor: 7.616

9.  Cerebellar atrophy in a patient with velocardiofacial syndrome.

Authors:  D R Lynch; D M McDonald-McGinn; E H Zackai; B S Emanuel; D A Driscoll; L A Whitaker; K H Fischbeck
Journal:  J Med Genet       Date:  1995-07       Impact factor: 6.318

10.  Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism.

Authors:  Thomas Foltynie; Terry E Goldberg; Simon G J Lewis; Andrew D Blackwell; Bhaskar S Kolachana; Daniel R Weinberger; Trevor W Robbins; Roger A Barker
Journal:  Mov Disord       Date:  2004-08       Impact factor: 10.338

View more
  21 in total

Review 1.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

2.  The curious case of a violently ill woman.

Authors:  John H Enterman; Dyllis van Dijk
Journal:  Schizophr Bull       Date:  2011-09-12       Impact factor: 9.306

Review 3.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

4.  Systems Analysis of the 22q11.2 Microdeletion Syndrome Converges on a Mitochondrial Interactome Necessary for Synapse Function and Behavior.

Authors:  Avanti Gokhale; Cortnie Hartwig; Amanda A H Freeman; Julia L Bassell; Stephanie A Zlatic; Christie Sapp Savas; Trishna Vadlamudi; Farida Abudulai; Tyler T Pham; Amanda Crocker; Erica Werner; Zhexing Wen; Gabriela M Repetto; Joseph A Gogos; Steven M Claypool; Jennifer K Forsyth; Carrie E Bearden; Jill Glausier; David A Lewis; Nicholas T Seyfried; Jennifer Q Kwong; Victor Faundez
Journal:  J Neurosci       Date:  2019-03-04       Impact factor: 6.167

5.  Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications.

Authors:  Nancy J Butcher; Tim-Rasmus Kiehl; Lili-Naz Hazrati; Eva W C Chow; Ekaterina Rogaeva; Anthony E Lang; Anne S Bassett
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

Review 6.  Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome.

Authors:  Nicole Philip; Anne Bassett
Journal:  Behav Genet       Date:  2011-05-15       Impact factor: 2.805

Review 7.  Neurogenetic disorders across the lifespan: from aberrant development to degeneration.

Authors:  Richard A Hickman; Sarah A O'Shea; Mark F Mehler; Wendy K Chung
Journal:  Nat Rev Neurol       Date:  2022-01-05       Impact factor: 42.937

Review 8.  Chromosome 22q11.2 deletion may contain a locus for recessive early-onset Parkinson's disease.

Authors:  Kotaro Ogaki; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2014-06-27       Impact factor: 4.891

9.  Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era.

Authors:  Gregory Costain; Anne S Bassett
Journal:  Appl Clin Genet       Date:  2012-02-20

10.  Role of vitamin d in Parkinson's disease.

Authors:  Khanh L Ng; Lan Nguyễn
Journal:  ISRN Neurol       Date:  2012-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.